Intake of dietary iron is low in patients with Crohn's disease: a case–control study

Lomer, Miranda; Kodjabashia, Kamelia; Hutchinson, Carol; Greenfield, S.; Thompson, R. P. H.; Powell, Jonathan J.

doi:10.1079/bjn20041022

Cited by 59 publications

(76 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, several studies demonstrated that oral iron induces oxidative stress in the gut and aggravates inflammation [11,27]. In IBD patients, there is often the need for high iron doses due to very low iron stores, resulting from chronic bleeding or inflammatory conditions [2,28,29]. …”

Section: Discussionmentioning

confidence: 99%

Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease

Beigel¹,

Löhr²,

Laubender

et al. 2011

Digestion

View full text Add to dashboard Cite

Background and Aims: We analyzed iron deficiency and the therapeutic response following intravenous ferric carboxymaltose in a large single-center inflammatory bowel disease (IBD) cohort. Methods: 250 IBD patients were retrospectively analyzed for iron deficiency and iron deficiency anemia. A subgroup was analyzed regarding efficacy and side effects of iron supplementation with ferric carboxymaltose. Results: In the cohort (n = 250), 54.4% of the patients had serum iron levels ≤60 µg/dl, 81.2% had ferritin ≤100 ng/ml, and 25.6% had hemoglobin (Hb) of ≤12 g/dl (females) or ≤13 g/dl (males). In the treatment subcohort (n = 80), 83.1% of the patients had iron ≤60 µg/dl, 90.4% had ferritin ≤100 ng/ml, and 66.7% had Hb ≤12/13 g/dl before ferric carboxymaltose treatment. After a median dose of 500 mg ferric carboxymaltose, 74.7% of the patients reached iron >60 µg/dl, 61.6% had ferritin >100 ng/ml, and 90.7% reached Hb >12/13 g/dl at follow-up (p < 0.0001 for all parameters vs. pretreatment values). The most frequent adverse event was a transient increase of liver enzymes with male gender as risk factor (p = 0.008, OR 8.62, 95% CI 1.74–41.66). Conclusions: Iron deficiency and anemia are frequent in IBD patients. Treatment with ferric carboxymaltose is efficious, safe and well tolerated in iron-deficient IBD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease

Beigel¹,

Löhr²,

Laubender

et al. 2011

Digestion

View full text Add to dashboard Cite

show abstract

“…The causes are multi-factorial with Fe deficiency and anaemia of chronic disease being the most common. Poor dietary Fe intakes (36) through avoidance of Fe-rich foods due to food aversions or intolerances may contribute to ongoing Fe deficiency but they are unlikely to be the only contributing factor to the anaemia in IBD (50) . In IBD, inflammation, Fe deficiency and anaemia of chronic disease often co-exist, making assessment of Fe status complex.…”

Section: Anaemiamentioning

confidence: 99%

Dietary and nutritional considerations for inflammatory bowel disease

Lomer

2011

Proc. Nutr. Soc.

Self Cite

View full text Add to dashboard Cite

Nutritional assessment and dietary advice are fundamental to inflammatory bowel disease (IBD) patient management and all patients should have access to a dietitian. Newly diagnosed patients often think that their pre-illness diet has contributed to the development of their IBD. However, epidemiological evidence to support diet as a risk factor is lacking. How the diet contributes to the gastrointestinal microbiota is interesting, although the role is not yet clearly defined. Nutritional problems in IBD are common. Malnutrition occurs in up to 85% of patients and weight loss affects up to 80% of patients with Crohn's disease and 18–62% of patients with ulcerative colitis. Nutritional deficiencies are prevalent, particularly in relation to anaemia and osteoporosis. Intestinal strictures can be problematic in Crohn's disease and limiting fibrous foods that may cause a mechanical obstruction in the gastrointestinal tract is helpful. Patients often explore dietary exclusion to alleviate symptoms but such changes may be self-directed or inappropriately advised and can lead to further nutritional deficiencies. Some patients experience concurrent functional symptoms (e.g. abdominal bloating, abdominal pain, flatulence and diarrhoea) that can significantly affect quality of life. Recently, a group of poorly absorbed carbohydrates that occur naturally in the diet called fermentable oligo-, di-, mono-saccharides and polyols have been associated with functional symptoms by intestinal bacterial fermentation leading to rapid gas production, and an osmotic effect increasing fluid delivery to the colon. Emerging evidence indicates that a diet low in fermentable oligo-, di-, mono-saccharides and polyols can alleviate functional symptoms in IBD.

show abstract

“…Iron deficiency anemia is the most prevalent cause for anemia in IBD, with an estimated prevalence of 36-76% depending on the population (outpatient vs. inpatient) [4,5] . Iron deficiency may be a consequence of dietary restrictions, malabsorption, or intestinal bleeding [6][7][8] .…”

Section: Introductionmentioning

confidence: 99%

Intravenous Iron Replacement Improves Quality of Life in Hypoferritinemic Inflammatory Bowel Disease Patients with and without Anemia

Eliadou

Kini²,

Huang³

et al. 2017

Dig Dis

View full text Add to dashboard Cite

Background: No study has compared changes in quality of life (QoL) following iron therapy between anemic and non-anemic, hypoferritinemic patients. This study compares the impact of parenteral iron replacement on QoL in inflammatory bowel disease (IBD) patients with anemia, or in those with hypoferritinemia alone. Methods: Consecutive IBD patients diagnosed with anemia or hypoferritinemia were enrolled. IBD questionnaire (IBDQ) and 36-Item Short Form Survey (SF36) at diagnosis and 6 weeks post treatment were measured. Results: Ten patients with anemia and 13 with hypoferritinemia were treated with intravenous iron polymaltose. Across all patients, there was a significant improvement in median SF36 mental component score by 8.5 (p = 0.004) and median IBDQ by 12 (p = 0.02). There was a trend towards improved median SF36 physical component score by 3.2 (p = 0.6). These changes were not significantly different when comparing anemic with hypoferritinemic patients. In IBDQ, there was a trend toward greater improvement in hypoferritinemic vs. anemic patients (20 vs. 1.5, p = 0.31). Conclusions: This is the first study to show that improvements in QoL in hypoferritinemic patients are similar to those with anemia. Based on these results, patients with IBD should be offered the option of iron therapy when they are found to be hypoferritinemic, even in the absence of anemia.

show abstract

Intake of dietary iron is low in patients with Crohn's disease: a case–control study

Cited by 59 publications

References 41 publications

Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease

Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease

Dietary and nutritional considerations for inflammatory bowel disease

Intravenous Iron Replacement Improves Quality of Life in Hypoferritinemic Inflammatory Bowel Disease Patients with and without Anemia

Contact Info

Product

Resources

About